Scientists at the Centre for Cancer Immunology have begun a new collaborative study to understand how therapeutic antibodies stimulate the body’s immune cells to kill other cells that contribute to a wide range of diseases, including cancer.
An engineered antibody, designed by a scientist now based at the Centre for Cancer Immunology, has shown it could help treat people with severe autoimmune diseases and also in the diagnostic imaging of cancer.
Professor Tim Elliott, Director of the Centre for Cancer Immunology, has been appointed as Founding Editor-In-Chief of the new journal Immunotherapy Advances.
Scientists at the Centre for Cancer Immunology alongside Cancer Research UK and Touchlight Genetics, a London based biotechnology company, have announced a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).
Scientists at the Centre for Cancer Immunology, University of Southampton, have discovered a way to transform antibody drugs previously developed to treated autoimmunity into antibodies with powerful anti-cancer activity through a simple molecular “switch”.
Professor Tim Elliott, Director for the Centre for Cancer Immunology, provides an update on Centre activity during the COVID-19 outbreak.
A simple lab-based blood test could potentially identify which cancer patients would get harmful side-effects from antibody immunotherapy treatment, a new Southampton study has shown.
A new research programme led by scientists at the Centre for Cancer Immunology will give important insight into an integral part of our immune system and the fight against cancer.
Scientists at the Centre for Cancer Immunology have been awarded £2.2million to develop the next generation of targeted therapy used to treat some cancers.
Centre Director Professor Tim Elliott takes a look back at 2018 – a pivotal year for the Centre for Cancer Immunology, its staff and the patients it was built to help.